润燥止痒胶囊联合枸地氯雷他定在治疗慢性荨麻疹中疗效的meta分析

Meta-analysis of the efficacy of Runzaozhiyang capsule combined with desloratadine citrate disodium in the treatment of chronic urticaria

目的评价润燥止痒胶囊联合枸地氯雷他定治疗慢性荨麻疹(CU)安全性和有效性。方法计算机检索Embase、Cochrane图书馆、PubMed、中国知网、万方数据库,纳入评价润燥止痒胶囊联合枸地氯雷他定治疗CU的随机对照试验,检索时间从建库到2021年6月。由两名作者提取资料、选取文献、并评价纳入文章的偏倚风险后,采用RevMan5.4软件进行meta分析。结果共纳入7项随机对照试验,包括611例CU患者,其中研究组307例,对照组304例。meta分析结果显示,研究组总有效率(OR=6.72,95%CI:3.62~12.46)、痊愈率(OR=1.93,95%CI:1.35~2.75)和降低免疫球蛋白E水平(MD=-34.54,95%CI:-39.12~-29.95)优于对照组,不良反应发生率(OR=0.36,95%CI:0.14~0.93,P<0.05)低于对照组,差异有统计学意义(P<0.05)。结论润燥止痒胶囊联合枸地氯雷他定治疗CU安全、有效。

Objective To review the efficacy and safety of Runzaozhiyang capsule with desloratadine citrate disodium in the treatment of chronic urticaria(CU).Methods The Cochrane Library,Embase,PubMed,CNKI,Wanfang Databases were retrieved and included in the randomized controlled trial of Runzaozhiyang capsule combined with desloratadine citrate disodium in the treatment of CU from the establishment of the database to June 2021.Two authors extracted data,selected literature,and evaluated the risk of bias in the included articles.Meta-analysis was performed using RevMan5.4.Results A total of seven randomized controlled trials were included in the analysis,including 611 patients,307 in the experimental group and 304 in the control group.The results of the meta-analysis showed that the total effective rate(OR=6.72,95%CI:3.62-12.46),the cure rate(OR=1.93,95%CI:1.35-2.75)and the reduction of immunoglobulin E level(MD=-34.54,95%CI:-39.12--29.95)in the experimental group was better than those in the control group,and the incidence of adverse reactions(OR=0.36,95%CI:0.14-0.93,P<0.05)was lower than that in the control group,the difference was statistically evident(P<0.05).Conclusion Runzaozhiyang capsule combined with desloratadine citrate disodium in the treatment of CU is safe and effective.